行情

INFI

INFI

Infinity制药
NASDAQ

实时行情|Nasdaq Last Sale

1.170
-0.020
-1.68%
休市 16:00 01/17 EST
开盘
1.190
昨收
1.190
最高
1.190
最低
1.160
成交量
16.70万
成交额
--
52周最高
1.950
52周最低
0.8200
市值
6,672.39万
市盈率(TTM)
-1.5179
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INFI 新闻

  • 中小科技企业抱怨:苹果谷歌等巨人让创新竞争不公平
  • 新浪数码.5小时前
  • 再结实的牛仔裤也挡不住零售业寒冬 真维斯破产清算
  • 新浪财经综合.5小时前
  • 财报季前夕猎豹移动更换CFO 来自人人公司
  • 新京报网.5小时前
  • 特朗普法律团队首次官方回应弹劾 否认指控
  • 央视.6小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

INFI 简况

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
展开

Webull提供Infinity Pharmaceuticals Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。